Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.

Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.

Item
http://www.wikidata.org/entity/Q41514433
Recent advances in primary Sjogren's syndromeMultiple Roles for B-Lymphocytes in Sjogren's SyndromeSerum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome.Salivary gland ultrasonography as a predictor of clinical activity in Sjögren's syndromeEffectiveness of Traditional Chinese Medicine Compound JieDuTongLuoShengJin Granules Treatment in Primary Sjögren's Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.Innate immunity in Sjögren's syndrome.Cutaneous and Mucosal Manifestations of Sjögren's Syndrome.Relationship Between Neuromyelitis Optica Spectrum Disorder and Sjögren's Syndrome: Central Nervous System Extraglandular Disease or Unrelated, Co-Occurring Autoimmunity?Patient burden of Sjögren's: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity.Chronic Autoimmune Epithelitis in Sjögren's Syndrome and Primary Biliary Cholangitis: A Comprehensive Review.Management of primary Sjögren's syndrome: recent developments and new classification criteria.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
P2860

Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.

Item
http://www.wikidata.org/entity/Q41514433
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy and safety of belimum ...... ISS open-label phase II study.
@en
type
label
Efficacy and safety of belimum ...... ISS open-label phase II study.
@en
prefLabel
Efficacy and safety of belimum ...... ISS open-label phase II study.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Efficacy and safety of belimum ...... ISS open-label phase II study.
@en
P2093
P2860
P304
P31
P356
10.1093/RHEUMATOLOGY/KEV257
P433
P478
P50
P577
P698